HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer
Author:
Affiliation:
1. Department of Medical Oncology Harbin Medical University Cancer Hospital Harbin Medical University Harbin China
2. Institute of Cancer Prevention and Treatment Heilongjiang Academy of Medical Sciences Harbin Medical University Harbin China
Funder
National Natural Science Foundation of China
Publisher
Wiley
Subject
Cancer Research,Oncology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14813
Reference44 articles.
1. Cancer statistics, 2019
2. Biological determinants of endocrine resistance in breast cancer
3. Endocrine resistance in breast cancer: Current status and a perspective on the roles of miRNAs (Review)
4. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies
5. Analysis of factors affecting endocrine therapy resistance in breast cancer
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. HMGB1 in the interplay between autophagy and apoptosis in cancer;Cancer Letters;2024-01
2. Strategy of combining CDK4/6 inhibitors with other therapies and mechanisms of resistance;International Journal of Clinical and Experimental Pathology;2024
3. Role and clinical significance of immunogenic cell death biomarkers in chemoresistance and immunoregulation of head and neck squamous cell carcinoma;Biomedicine & Pharmacotherapy;2023-11
4. Circ_LRP6 facilitates osteosarcoma progression via the miR‐122‐5p/miR‐204‐5p/HMGB1 axis;Environmental Toxicology;2023-07-14
5. Mechanisms involved in the HMGB1 modulation of tumor multidrug resistance (Review);International Journal of Molecular Medicine;2023-06-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3